Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Payables (2017 - 2025)

Historic Payables for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $7.0 million.

  • Sutro Biopharma's Payables rose 1315.96% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 1315.96%. This contributed to the annual value of $10.5 million for FY2024, which is 1096.4% up from last year.
  • As of Q3 2025, Sutro Biopharma's Payables stood at $7.0 million, which was up 1315.96% from $4.3 million recorded in Q2 2025.
  • Sutro Biopharma's 5-year Payables high stood at $12.6 million for Q2 2022, and its period low was $3.9 million during Q2 2023.
  • Its 5-year average for Payables is $7.6 million, with a median of $7.0 million in 2025.
  • As far as peak fluctuations go, Sutro Biopharma's Payables surged by 12900.18% in 2021, and later crashed by 6931.65% in 2023.
  • Sutro Biopharma's Payables (Quarter) stood at $6.0 million in 2021, then decreased by 20.17% to $4.8 million in 2022, then surged by 96.79% to $9.4 million in 2023, then grew by 10.96% to $10.5 million in 2024, then tumbled by 32.85% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q3 2025, $4.3 million for Q2 2025, and $8.2 million during Q1 2025.